Please login to the form below

Not currently logged in
Email:
Password:

S-A/ Avila sign oncology drug deal

Sanofi-aventis has announced a worldwide strategic alliance with Avila Therapeutics focusing on the discovery of covalent drugs for cancers

Sanofi-aventis (S-A) has announced a worldwide strategic alliance with Avila Therapeutics focusing on the discovery of covalent drugs for use in oncology treatments.

The deal allows S-A to obtain a global licence to develop and market compounds resulting from the partnership. Avila will receive up to $40m in upfront and support payments, with milestone payments of up to $154m per collaboration programme also available if the developed product is approved in the US, Europe and Japan.

There will be six collaboration programmes in total, with the companies working together using Avila's Avilomics platform to design products which aim to target one of six signalling proteins that are critical in tumour cells.

These proteins are difficult to target with conventional pharmaceutical treatments, but are thought to have the potential to respond to covalent drugs.

Covalent treatments have the ability to establish a stronger molecular bond than conventional therapies, allowing them to shut down the activity of proteins responsible for certain diseases. This technique is called 'protein silencing'.

"Avila Therapeutics' expertise in designing targeted covalent drugs offers a new way to solve difficult pharmacological challenges in oncology and to address important cancer targets," said Dr Debasish Roychowdhury, senior vice president and head of oncology, S-A. "We believe that Avila's approach adds to our growing portfolio of research capabilities that will provide medicines which substantially improve patient outcomes."

20th December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics